Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIVOPTIMIZE: Nivolumab dose optimization in responding melanoma or renal cell carcinoma patients
2024-516718-39-00Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nivolumab in melanoma and renal cell carcinoma (RCC), sponsored by Erasmus MC. Primary endpoint: Primary: Difference in mean nivolumab trough levels. Planned start Aug 2024; status: authorised.
02
Drugs
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-516718-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516718-39-00.